Literature DB >> 16237375

Influenza vaccination levels among persons aged > or =65 years and among persons aged 18-64 years with high-risk conditions--United States, 2003.

.   

Abstract

Influenza vaccination is an effective tool for preventing hospitalization and death among persons aged > or =65 years and among persons aged 18-64 years with medical conditions that increase the risk for influenza-related complications. Two national health objectives for 2010 are to increase influenza vaccination coverage to 90% among persons aged > or =65 years and to 60% among persons aged 18-64 years who have one or more high-risk conditions (objectives 14-29a and 14-29c, respectively). To determine influenza vaccination coverage among persons in both targeted groups, CDC analyzed data from the 2003 National Health Interview Survey (NHIS). This report summarizes the results of that analysis, which determined that influenza vaccination coverage among persons aged > or =65 years and persons aged 18-64 years with high-risk conditions remains substantially below 2010 target levels. In addition, racial/ethnic disparities in coverage levels persist in both targeted populations. To improve overall influenza vaccination coverage and reduce racial/ethnic disparities, combinations of evidence-based effective interventions should be implemented, and the influenza vaccine supply should be stabilized.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237375

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  9 in total

1.  Impact of the 2004 influenza vaccine shortage on patients from inner city health centers.

Authors:  Richard K Zimmerman; Melissa Tabbarah; Mary Patricia Nowalk; Mahlon Raymund; Stephen A Wilson; Ann McGaffey; J Todd Wahrenberger; Bruce Block; Edmund M Ricci
Journal:  J Urban Health       Date:  2007-05       Impact factor: 3.671

2.  Seasonal influenza in the United States, France, and Australia: transmission and prospects for control.

Authors:  G Chowell; M A Miller; C Viboud
Journal:  Epidemiol Infect       Date:  2007-07-18       Impact factor: 2.451

3.  Pandemic influenza preparedness and response among public-housing residents, single-parent families, and low-income populations.

Authors:  Karen Bouye; Benedict I Truman; Sonja Hutchins; Roland Richard; Clive Brown; Joyce A Guillory; Jamila Rashid
Journal:  Am J Public Health       Date:  2009-10       Impact factor: 9.308

4.  Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.

Authors:  Karen M Clements; Genevieve Meier; Lisa J McGarry; Narin Pruttivarasin; Derek A Misurski
Journal:  Hum Vaccin Immunother       Date:  2014-03-07       Impact factor: 3.452

5.  Racial/Ethnic Disparities in Influenza Vaccination of Chronically Ill US Adults: The Mediating Role of Perceived Discrimination in Health Care.

Authors:  William K Bleser; Patricia Y Miranda; Muriel Jean-Jacques
Journal:  Med Care       Date:  2016-06       Impact factor: 2.983

6.  Factors contributing to suboptimal vaccination against influenza: results of a nationwide telephone survey of persons with cardiovascular disease.

Authors:  Mohammad Madjid; Anushayanthan Alfred; Achal Sahai; Jodie L Conyers; S Ward Casscells
Journal:  Tex Heart Inst J       Date:  2009

7.  Novel virus, atypical risk group: understanding young adults in college as an under-protected population during H1N1 2009.

Authors:  Karl Maier; Jennifer Berkman; David Chatkoff
Journal:  PLoS Curr       Date:  2012-12-20

8.  Vaccination rates among the general adult population and high-risk groups in the United States.

Authors:  Kathy Annunziata; Aaron Rak; Heather Del Buono; Marco DiBonaventura; Girishanthy Krishnarajah
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

9.  Pandemic influenza planning in the United States from a health disparities perspective.

Authors:  Philip Blumenshine; Arthur Reingold; Susan Egerter; Robin Mockenhaupt; Paula Braveman; James Marks
Journal:  Emerg Infect Dis       Date:  2008-05       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.